Biotechnology company Immutep
(ASX:IMM) has reached the mid-point in patient enrolment for its ongoing AIPAC Phase IIb clinical trial evaluating eftilagimod alpha in combination with paclitaxel in metastatic breast cancer.
In 2018 clinical trial sites were opened in Germany, the UK, France and Hungary complementing the existing active sites in Belgium, Poland and the Netherlands, thereby leading to an acceleration of the monthly recruitment rate.
All clinical sites are now actively recruiting and treating patients as part of the randomised and controlled phase of the study.
The primary clinical end-point of the study is Progression-Free Survival.
From a commercial perspective, there is a great deal of interest from patients, clinicians, and investors in the LAG-3 immune control mechanism.
Shares in Immutep
(ASX:IMM) are trading flat at 3c.
